Viracta Therapeutics, Inc. (VIRX)
NASDAQ: VIRX · Real-Time Price · USD
0.162
-0.005 (-2.82%)
Jan 22, 2025, 12:56 PM EST - Market open
Viracta Therapeutics Employees
Viracta Therapeutics had 40 employees as of December 31, 2023. The number of employees increased by 8 or 25.00% compared to the previous year.
Employees
40
Change (1Y)
8
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,082,225
Market Cap
6.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 40 | 8 | 25.00% |
| Dec 31, 2022 | 32 | 8 | 33.33% |
| Dec 31, 2021 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
VIRX News
- 26 days ago - Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - GlobeNewsWire
- 2 months ago - Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - GlobeNewsWire
- 8 months ago - Viracta Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 9 months ago - Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - GlobeNewsWire
- 9 months ago - Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewsWire